Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.32%
+1.99%
+2.67%
+0.07%
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
24 Feb 2026$CLVT delivered a Q4 earnings beat on both revenue and adjusted EPS while also swinging back to profitability, a sharp contrast to last year’s loss. Traders are also reacting to reports the company is exploring a sale of its Life Sciences & Healthcare segment, which introduces a potential strategic revaluation story. With volume exploding far beyond its normal baseline, the move looks less like a casual bounce and more like funds repositioning around a restructuring narrative.
$PVLA is ripping higher after clinical trial news gave biotech traders exactly what they look for: clear Phase 3 success. Palvella Therapeutics reported positive topline data from its SELVA study evaluating QTORIN for microcystic lymphatic malformations. Late-stage trial wins tend to reset expectations quickly because they move a therapy materially closer to commercialization. The surge in price alongside volume multiples above average suggests speculative capital rotating into the name ahead of deeper analysis of the data.
$LRMR is moving more on activity than a single headline, but sometimes that is the headline. Larimar Therapeutics landed on multiple most-active lists during the session and the volume spike is extreme relative to its historical trading profile. When a stock trades tens of millions of shares against a typical fraction of that, it usually means short-term traders and momentum funds have discovered it at the same time. These liquidity events can create fast price expansion simply because supply disappears once the tape accelerates.
$GANX has quietly built momentum that is now attracting attention. Gain Therapeutics is extending a multi-day rally, marking its fifth straight session higher. Streaks like this often pull in technical traders scanning for relative strength rather than reacting to a single news item. The steady climb combined with expanding participation suggests positioning ahead of potential updates or simply a shift in sentiment toward smaller biotech names.
$IOVA is seeing renewed interest after updates tied to its latest earnings cycle and continued demand commentary. Iovance Biotherapeutics highlighted strong quarterly progress with revenue growth driven by Amtagvi adoption, while results also came in ahead of expectations on sales. The stock has now stacked multiple positive sessions in a row, and the heavy trading volume indicates institutions and momentum traders are both involved in the move.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 5,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Pro Members
